Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent

The spread of multidrug resistance among bacterial pathogens poses a serious threat to public health worldwide. Recent approaches towards combating antimicrobial resistance include repurposing old compounds with known safety and development pathways as new antibacterial classes with novel mechanisms...

Full description

Bibliographic Details
Main Authors: Ogunniyi, A., Khazandi, M., Stevens, A., Sims, S., Page, S., Garg, S., Venter, H., Powell, A., White, K., Petrovski, K., Laven-Law, G., Tótoli, E., Salgado, H., Pi, H., Coombs, Geoffrey, Shinabarger, D., Turnidge, J., Paton, J., McCluskey, A., Trott, D.
Format: Journal Article
Published: Public Library of Science 2017
Online Access:http://hdl.handle.net/20.500.11937/70126
_version_ 1848762222110572544
author Ogunniyi, A.
Khazandi, M.
Stevens, A.
Sims, S.
Page, S.
Garg, S.
Venter, H.
Powell, A.
White, K.
Petrovski, K.
Laven-Law, G.
Tótoli, E.
Salgado, H.
Pi, H.
Coombs, Geoffrey
Shinabarger, D.
Turnidge, J.
Paton, J.
McCluskey, A.
Trott, D.
author_facet Ogunniyi, A.
Khazandi, M.
Stevens, A.
Sims, S.
Page, S.
Garg, S.
Venter, H.
Powell, A.
White, K.
Petrovski, K.
Laven-Law, G.
Tótoli, E.
Salgado, H.
Pi, H.
Coombs, Geoffrey
Shinabarger, D.
Turnidge, J.
Paton, J.
McCluskey, A.
Trott, D.
author_sort Ogunniyi, A.
building Curtin Institutional Repository
collection Online Access
description The spread of multidrug resistance among bacterial pathogens poses a serious threat to public health worldwide. Recent approaches towards combating antimicrobial resistance include repurposing old compounds with known safety and development pathways as new antibacterial classes with novel mechanisms of action. Here we show that an analog of the anticoccidial drug robenidine (4,6-bis(2-((E)-4-methylbenzylidene)hydrazinyl)pyrimidin-2-amine; NCL195) displays potent bactericidal activity against Streptococcus pneumoniae and Staphylococcus aureus by disrupting the cell membrane potential. NCL195 was less cytotoxic to mammalian cell lines than the parent compound, showed low metabolic degradation rates by human and mouse liver microsomes, and exhibited high plasma concentration and low plasma clearance rates in mice. NCL195 was bactericidal against Acinetobacter spp and Neisseria meningitidis and also demonstrated potent activity against A. baumannii, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and Enterobacter spp. in the presence of sub-inhibitory concentrations of ethylenediaminetetra-acetic acid (EDTA) and polymyxin B. These findings demonstrate that NCL195 represents a new chemical lead for further medicinal chemistry and pharmaceutical development to enhance potency, solubility and selectivity against serious bacterial pathogens.
first_indexed 2025-11-14T10:44:08Z
format Journal Article
id curtin-20.500.11937-70126
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T10:44:08Z
publishDate 2017
publisher Public Library of Science
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-701262018-08-23T00:53:17Z Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent Ogunniyi, A. Khazandi, M. Stevens, A. Sims, S. Page, S. Garg, S. Venter, H. Powell, A. White, K. Petrovski, K. Laven-Law, G. Tótoli, E. Salgado, H. Pi, H. Coombs, Geoffrey Shinabarger, D. Turnidge, J. Paton, J. McCluskey, A. Trott, D. The spread of multidrug resistance among bacterial pathogens poses a serious threat to public health worldwide. Recent approaches towards combating antimicrobial resistance include repurposing old compounds with known safety and development pathways as new antibacterial classes with novel mechanisms of action. Here we show that an analog of the anticoccidial drug robenidine (4,6-bis(2-((E)-4-methylbenzylidene)hydrazinyl)pyrimidin-2-amine; NCL195) displays potent bactericidal activity against Streptococcus pneumoniae and Staphylococcus aureus by disrupting the cell membrane potential. NCL195 was less cytotoxic to mammalian cell lines than the parent compound, showed low metabolic degradation rates by human and mouse liver microsomes, and exhibited high plasma concentration and low plasma clearance rates in mice. NCL195 was bactericidal against Acinetobacter spp and Neisseria meningitidis and also demonstrated potent activity against A. baumannii, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and Enterobacter spp. in the presence of sub-inhibitory concentrations of ethylenediaminetetra-acetic acid (EDTA) and polymyxin B. These findings demonstrate that NCL195 represents a new chemical lead for further medicinal chemistry and pharmaceutical development to enhance potency, solubility and selectivity against serious bacterial pathogens. 2017 Journal Article http://hdl.handle.net/20.500.11937/70126 10.1371/journal.pone.0183457 http://creativecommons.org/licenses/by/4.0/ Public Library of Science fulltext
spellingShingle Ogunniyi, A.
Khazandi, M.
Stevens, A.
Sims, S.
Page, S.
Garg, S.
Venter, H.
Powell, A.
White, K.
Petrovski, K.
Laven-Law, G.
Tótoli, E.
Salgado, H.
Pi, H.
Coombs, Geoffrey
Shinabarger, D.
Turnidge, J.
Paton, J.
McCluskey, A.
Trott, D.
Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent
title Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent
title_full Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent
title_fullStr Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent
title_full_unstemmed Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent
title_short Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent
title_sort evaluation of robenidine analog ncl195 as a novel broad-spectrum antibacterial agent
url http://hdl.handle.net/20.500.11937/70126